Who are BDL regimen's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Treatment regimens for MDR-TB.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/bdl-regimen.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

BDL regimen — Competitive Intelligence Brief

BDL regimen (BDL regimen) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anti-tuberculous combination therapy. Area: Infectious Disease.

marketed Anti-tuberculous combination therapy Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

BDL regimen (BDL regimen) — Beijing Chest Hospital. BDL is a combination chemotherapy regimen used to treat tuberculosis by combining multiple anti-tuberculous agents.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
BDL regimen TARGET	BDL regimen	Beijing Chest Hospital	marketed	Anti-tuberculous combination therapy
Treatment regimens for MDR-TB	Treatment regimens for MDR-TB	Shanghai Pulmonary Hospital, Shanghai, China	marketed	Anti-tuberculous combination therapy

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anti-tuberculous combination therapy class)

Beijing Chest Hospital · 1 drug in this class
Shanghai Pulmonary Hospital, Shanghai, China · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). BDL regimen — Competitive Intelligence Brief. https://druglandscape.com/ci/bdl-regimen. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab